Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRoland SchroersIBIgor Wolfgang BlauSLSteffen Luntz

Discussion

Loading...

Member takes

Overview

Monitoring minimal residual disease shows significant prognostic value for progression free survival in double-negative patients with multiple myeloma.

Key Points

  • To evaluate the significance of peripheral residual disease assessment in newly-diagnosed multiple myeloma using mass spectrometry.
  • Analyzed serum samples from 622 patients in the GMMG-HD7 trial.
  • Used MALDI-TOF mass spectrometry to assess minimal residual disease levels.
  • Performed progression free survival analysis with Kaplan-Meier and Cox regression methods.
  • Post IND, ASCT, and MT12 showed 22%, 49%, and 79% of patients were PRD-negative.
  • PRD negativity strongly correlated with improved progression free survival metrics.
  • Double-negative patients exhibited superior outcomes compared to double-positive cases.

Cite This Study

Schroers et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc86https://doi.org/10.1182/blood-2025-920
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial2025
  2. 2Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma2024 · 17 citations
  3. 3P11 | PERIPHERAL MEASURABLE RESIDUAL DISEASE ACTIVITY ASSESSMENT BY MALDI-TOF MASS SPECTROMETRY IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA IN THE PHASE 3 GMMG-HD7 TRIAL2026
  4. 4Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)2025
  5. 5Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025